FibroBiologics, Inc. Common Stock (FBLG) Financial Ratios
6 years of historical data (2020–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
0.45
↓-96% vs avg
5yr avg: 12.84
30Y Low1.6·High24.0
ROE
↑
-419.4%
↓+45% vs avg
5yr avg: -764.9%
30Y Low-419%·High-419%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
FBLG Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
FibroBiologics, Inc. Common Stock currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Market Cap | $3M | $10M | $66M | — | — | — | — |
| Enterprise Value | $115005 | $8M | $62M | — | — | — | — |
| P/E Ratio → | -0.15 | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — |
| P/B Ratio | 0.45 | 1.63 | 24.04 | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
FBLG EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — |
FBLG Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -419.4% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| ROE | -419.4% | -419.4% | -559.7% | -1315.6% | — | — | — |
| ROA | -143.1% | -143.1% | -79.0% | -198.1% | -193.5% | -338.0% | — |
| ROIC | -839.4% | -839.4% | — | — | -774.6% | — | — |
| ROCE | -287.6% | -287.6% | -432.2% | -4570.2% | — | — | — |
FBLG Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $5M exceeds total debt of $2M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.39 | 0.39 | 3.86 | 1.39 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.40 | -1.25 | -5.92 | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — |
| Interest Coverage | -90.40 | -90.40 | -557.05 | -111.14 | -6.83 | -394.50 | — |
Net cash position: cash ($5M) exceeds total debt ($2M)
FBLG Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
FibroBiologics, Inc. Common Stock's current ratio of 3.61x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 1.00x to 3.61x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 3.61 | 3.61 | 1.12 | 1.00 | 0.37 | 0.27 | — |
| Quick Ratio | 3.61 | 3.61 | 1.12 | 1.00 | 0.37 | 0.27 | — |
| Cash Ratio | 2.78 | 2.78 | 1.10 | 1.00 | 0.32 | 0.23 | — |
| Asset Turnover | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — |
FBLG Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
FibroBiologics, Inc. Common Stock does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $2M | $2M | $2M | $2M | $2M | $2M |
Peer Comparison
Compare FBLG with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 FBLGYou | $3M | -0.1 | — | — | — | — | -419.4% | -839.4% | — |
 MESO | $2B | -17.6 | — | — | 70.2% | -363.1% | -19.0% | -8.5% | — |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 MDXG | $548M | 11.5 | 5.1 | 7.5 | 82.6% | 15.3% | 21.6% | 42.3% | 0.3 |
 RGEN | $7B | 147.0 | 52.4 | 75.9 | 47.1% | 8.1% | 2.4% | 2.2% | 5.0 |
 FATE | $280M | -2.1 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 CELC | $6B | -46.2 | — | — | — | — | -87.5% | -50.3% | — |
 VCEL | $2B | 109.8 | 79.8 | 72.3 | 74.4% | 4.0% | 5.1% | 2.5% | 4.4 |
 RCUS | $2B | -7.5 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 ILMN | $21B | 25.5 | 19.6 | 22.6 | 66.7% | 19.9% | 33.4% | 16.8% | 2.3 |
 TMO | $176B | 26.8 | 19.0 | 28.0 | 37.7% | 18.2% | 13.1% | 7.5% | 3.8 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 6 years · Updated daily
See FBLG's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs FBLG Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare FBLG vs MESO
Side-by-side business, growth, and profitability comparison vs Mesoblast Limited.
Start ComparisonFBLG — Frequently Asked Questions
Quick answers to the most common questions about buying FBLG stock.
What is FibroBiologics, Inc. Common Stock's P/E ratio?
FibroBiologics, Inc. Common Stock's current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
What is FibroBiologics, Inc. Common Stock's ROE?
FibroBiologics, Inc. Common Stock's return on equity (ROE) is -419.4%. The historical average is -419.4%.
Is FBLG stock overvalued?
Based on historical data, FibroBiologics, Inc. Common Stock is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.